Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 23, 2022 10:37am
137 Views
Post# 35189378

RE:RE:RE:RE:RE:RE:RE:RE:Newbies...ignore the vapid FUD attempts...

RE:RE:RE:RE:RE:RE:RE:RE:Newbies...ignore the vapid FUD attempts...Lesalpes, let's just clear htis up once and for all shall we. No-one works for me, I do not short, nor do I work in finance. I'm a retail investor like most here.

NO matter, when ONCY announces in 2023 that they're not going to run the Phase III for mBC, you can thank me for having bailed now.

For all this marvellous data, there is practically zero institutional interest in this company...All I see is pps destruction of over 96% in 25 years, years of delayed trials, inconclusive results from every trial (due to too few patients on trial), and BS from senior management.

I'm not bashing Pelareorep, I'm bashing its management team for failing spectacularly to get this further than it is. WE still DO NOT know conclusively if Pela+Pax+CPI is better than Pela+Pax. And if it isn't, then the last 5 years were a complete waste of time and money... your money, and my money.
<< Previous
Bullboard Posts
Next >>